← Back to Search

Radiation Therapy

Stereotactic Ablative Radiation Therapy for Kidney Cancer

Phase 2

Waitlist Available

Led By Raquibul Hannan, MD, PhD

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of the study

Biopsy proven Renal neoplasm

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is testing a new, non-invasive treatment for small renal tumors. The goal is to see if it is effective.

Who is the study for?

This trial is for adults with small kidney tumors (≤5cm) that have been biopsy-proven and shown growth. Participants must be able to undergo MRI or CT scans, use effective contraception if of childbearing potential, and not be pregnant. Those who've had prior treatments for the renal mass or have metastatic disease (with exceptions) can't join.Check my eligibility

What is being tested?

The study is testing Stereotactic Ablative Radiation Therapy (SABR), a non-invasive treatment targeting small growing renal tumors. It's a phase II trial aiming to assess how well this therapy works in eliminating cancer cells without surgery.See study design

What are the potential side effects?

Potential side effects of SABR may include fatigue, skin reactions at the treatment site, nausea, changes in urinary habits, and abdominal pain. The exact side effects can vary based on individual patient factors.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I agree to use effective birth control or abstain from sex during the study.

Select...

My kidney tumor was confirmed by a biopsy.

Select...

My kidney cancer includes all types, even oncocytoma.

Select...

I am 18 years old or older.

Select...

My kidney tumor grew more than 2mm in a year.

Select...

I am a woman who could still become pregnant.

Select...

My kidney tumor is 5cm or smaller.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Eliminate its growth and tumor viability.

Secondary outcome measures

Adverse events

Renal function

Tumor Viability

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Stereotactic Ablative Radiation TherapyExperimental Treatment1 Intervention

Stereotactic Ablative Radiation Therapy (SABR)

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,047 Previous Clinical Trials

1,053,783 Total Patients Enrolled

Raquibul Hannan, MD, PhDPrincipal InvestigatorUTSW

5 Previous Clinical Trials

100 Total Patients Enrolled

Media Library

Stereotactic Ablative Radiation Therapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02141919 — Phase 2

Kidney Cancer Research Study Groups: Stereotactic Ablative Radiation Therapy

Kidney Cancer Clinical Trial 2023: Stereotactic Ablative Radiation Therapy Highlights & Side Effects. Trial Name: NCT02141919 — Phase 2

Stereotactic Ablative Radiation Therapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02141919 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical trial recruiting elderly individuals?

"The criteria for inclusion in this clinical trial restricts participants to those between 18 and 99 years of age. Additionally, there are 31 studies available for minors under the age of 18 and 409 specialized studies catering to individuals over 65."

Answered by AI

Has the FDA provided approval for Stereotactic Ablative Radiation Therapy?

"Although there is limited data that vouch for the safety of Stereotactic Ablative Radiation Therapy, it still attained a score of 2 on our team's scale due to being in Phase 2."

Answered by AI

Are there still opportunities to join this medical trial?

"As indicated on clinicaltrials.gov, recruitment for this medical trial has ceased; the study was first posted in June 2013 and last updated in August 2022. Fortunately, there are 423 other trials actively enrolling patients at present."

Answered by AI

Am I able to partake in this research trial?

"This study is enrolling 16 people aged between 18 and 99 with renal cancer. Additional criteria that must be met include: not having undergone a hysterectomy or bilateral oophorectomy, still experiencing menstrual cycles in the last twelve months, and the treating renal mass measuring no more than 5cm. Other smaller masses do not preclude eligibility for participation."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer

Raquibul Hannan 2013. "Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02141919.

All > Renal Cancer > Kidney Cancer